L3VLUP
ProSign in

ALGN · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ALGNJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ALGN
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterALGNJNJ
Q3 202022 holders, $4.0bn30 holders, $26.2bn
Q4 202021 holders, $6.4bn32 holders, $26.6bn
Q1 202130 holders, $6.5bn31 holders, $25.3bn
Q2 202129 holders, $6.5bn37 holders, $25.6bn
Q3 202126 holders, $8.1bn40 holders, $24.1bn
Q4 202121 holders, $8.4bn33 holders, $25.2bn
Q1 202220 holders, $6.1bn35 holders, $28.2bn
Q2 202217 holders, $3.4bn33 holders, $26.9bn
Q3 202219 holders, $2.7bn36 holders, $25.4bn
Q4 202216 holders, $2.2bn35 holders, $27.6bn
Q1 202319 holders, $3.8bn42 holders, $24.5bn
Q2 202320 holders, $4.1bn38 holders, $25.0bn
Q3 202318 holders, $2.9bn37 holders, $18.9bn
Q4 202320 holders, $2.4bn31 holders, $19.0bn
Q1 202419 holders, $2.7bn32 holders, $19.7bn
Q2 202418 holders, $1.6bn35 holders, $20.4bn
Q3 202415 holders, $2.1bn28 holders, $22.3bn
Q4 202417 holders, $1.5bn37 holders, $20.4bn
Q1 202517 holders, $1.3bn32 holders, $20.5bn
Q2 202517 holders, $1.5bn31 holders, $18.4bn
Q3 202511 holders, $751m32 holders, $23.7bn
Q4 202514 holders, $1.0bn29 holders, $27.8bn
Q1 202610 holders, $1.3bn34 holders, $35.6bn
Q2 202610 holders, $1.9bn33 holders, $39.1bn
ALGN

Align Technology Inc

Holders
17
Reported value
$1.3bn
Buyers
11
Sellers
7

Breadth +4 among 95 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
JNJ

Johnson & Johnson

Holders
32
Reported value
$20.5bn
Buyers
16
Sellers
15

Breadth +1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2025

Among the 39 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ALGN (7)

ARK Investment Management LLC, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, ExodusPoint Capital Management LP, First Eagle Investment Management LLC, Voloridge Investment Management LLC

Only JNJ (22)

AllianceBernstein LP, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, D. E. Shaw & Co., Dodge & Cox, Element Capital Management LLC, Fidelity (FMR LLC), GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Markel Group Inc, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →